The intervention involves administering ceralasertib, an experimental drug, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily for a week, while the other drugs are administered in single ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

Pamplona will pay $88.10 per share in cash for Parexel, representing a 5 percent premium to the stock's Monday close. Parexel's shares were trading at $87.67 before the bell, just shy of the offer ...

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications ...

25-year industry veteran and Biotech business leader recognized among the most inspiring people in life sciencesBOSTON and DURHAM, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading ...

PAREXEL has overcome this by creating a knowledge repository called SIMS (Site Intelligence Management System) that collects data on investigator performance from numerous different sources.

Parexel’s commitment towards being a diverse organization that builds on its employees’ skills to deliver groundbreaking work is considered to be one of the greatest motivations for employees ...

Parexel was founded in 1982 and is led by Jamie McDonald, who prior to his role at the CRO was a senior advisor to EQT. Parexel’s headcount is approximately 17,000.

Parexel, which conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process, has been an IFS customer for the past 15 years.

PAREXEL now offers end-to-end expertise for the design, development, and delivery of managed access programs to help biopharmaceutical companies provide access to investigational medical products ...

For the full fiscal year, Parexel cranked out $1.7 billion in revenue, a 24% jump over 2012, and, thanks to its recent acquisitions and expanding market share, the CRO is expecting up to $1.9 ...

Parexel, the Newton-based company that helps run clinical trials for the pharmaceutical industry, said Friday it would be bought by the Swedish private equity firm EQT and Goldman Sachs Asset ...